Survival Outcomes after Hyperthermic Intraperitoneal Chemotherapy for a First Ovarian Cancer Relapse: A Systematic Evidence-Based Review
Hyperthermic intraperitoneal chemotherapy (HIPEC) is routinely used in the treatment of a first ovarian cancer relapse. This systematic review, in accordance with Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, aimed to assess the quality of scientific proof of the sur...
Gespeichert in:
| Veröffentlicht in: | Cancers 2021-12, Vol.14 (1), p.172 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | 172 |
| container_title | Cancers |
| container_volume | 14 |
| creator | Classe, Jean-Marc Asselain, Bernard Campion, Loic Berton, Dominique Frenel, Jean-Sébastien Lécuru, Fabrice Ferron, Gwenael Gladieff, Laurence Bourgin, Charlotte Loaec, Cecile |
| description | Hyperthermic intraperitoneal chemotherapy (HIPEC) is routinely used in the treatment of a first ovarian cancer relapse.
This systematic review, in accordance with Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, aimed to assess the quality of scientific proof of the survival benefits of HIPEC, using Medline and Google Scholar. Qualitative analysis using the Oxford CEBM Levels of Evidence 2011 grading is reported.
Of 469 articles identified, 23 were included; 15 based on series of patients treated with HIPEC without a control group, and 8 case control series of patients treated with or without HIPEC. The series without a control group showed median overall survival (OS) ranged from 23.5 to 63 months, highlighting a broad standard deviation. Considering the case control series, OS was significantly better in the HIPEC group in 5 studies, and similar in 1. The current review showed considerable heterogeneity and biases, with an Oxford Level of Evidence grading of 4 for 22 selected series and 2 for one.
There is no strong evidence to suggest efficacy of HIPEC in improving survival of patients treated for a first relapse of ovarian cancer due to the low quality of the data. |
| doi_str_mv | 10.3390/cancers14010172 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8750536</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2618209057</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-5b1a3c671811af9f61ef2b0b7a2f5ba08f0ace2425f96ed614bfaad6648278e33</originalsourceid><addsrcrecordid>eNpdkUtr3DAUhUVpaUKadXdF0E03TvSwZbuLQjrkBYGBJF2ba_mqo2BbriS7zD_Iz44mSUMabaTL-XS4h0PIZ86OpKzZsYZRow88Z5zxUrwj-4KVIlOqzt-_eu-RwxDuWDpS8lKVH8meLBirpFT75P5m9otdoKfrOWo3YKBgInp6sZ3Qxw36wWp6OUYPabbRjZjY1QYHtxNh2lLjPAV6Zn2IdL2AtzDS1eNq9Bp7mAJ-pyf0ZhsiDhCT2-liO0x69hMCdglaLP79RD4Y6AMePt8H5NfZ6e3qIrtan1-uTq4ynQses6LlILUqecU5mNoojka0rC1BmKIFVhkGGkUuClMr7BTPWwPQKZVXoqxQygPy48l3mtsBO427aH0zeTuA3zYObPO_MtpN89stTVUWrJAqGXx7NvDuz4whNoMNGvseRnRzaITiVc2qutqhX9-gd272Y4r3SAlWs6JM1PETpb0LwaN5WYazZld086bo9OPL6wwv_L9a5QOrS6hD</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2618209057</pqid></control><display><type>article</type><title>Survival Outcomes after Hyperthermic Intraperitoneal Chemotherapy for a First Ovarian Cancer Relapse: A Systematic Evidence-Based Review</title><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Classe, Jean-Marc ; Asselain, Bernard ; Campion, Loic ; Berton, Dominique ; Frenel, Jean-Sébastien ; Lécuru, Fabrice ; Ferron, Gwenael ; Gladieff, Laurence ; Bourgin, Charlotte ; Loaec, Cecile</creator><creatorcontrib>Classe, Jean-Marc ; Asselain, Bernard ; Campion, Loic ; Berton, Dominique ; Frenel, Jean-Sébastien ; Lécuru, Fabrice ; Ferron, Gwenael ; Gladieff, Laurence ; Bourgin, Charlotte ; Loaec, Cecile</creatorcontrib><description>Hyperthermic intraperitoneal chemotherapy (HIPEC) is routinely used in the treatment of a first ovarian cancer relapse.
This systematic review, in accordance with Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, aimed to assess the quality of scientific proof of the survival benefits of HIPEC, using Medline and Google Scholar. Qualitative analysis using the Oxford CEBM Levels of Evidence 2011 grading is reported.
Of 469 articles identified, 23 were included; 15 based on series of patients treated with HIPEC without a control group, and 8 case control series of patients treated with or without HIPEC. The series without a control group showed median overall survival (OS) ranged from 23.5 to 63 months, highlighting a broad standard deviation. Considering the case control series, OS was significantly better in the HIPEC group in 5 studies, and similar in 1. The current review showed considerable heterogeneity and biases, with an Oxford Level of Evidence grading of 4 for 22 selected series and 2 for one.
There is no strong evidence to suggest efficacy of HIPEC in improving survival of patients treated for a first relapse of ovarian cancer due to the low quality of the data.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers14010172</identifier><identifier>PMID: 35008336</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Cancer therapies ; Chemotherapy ; Clinical trials ; Morbidity ; Ovarian cancer ; Patients ; Surgery ; Survival ; Systematic Review ; Tumors</subject><ispartof>Cancers, 2021-12, Vol.14 (1), p.172</ispartof><rights>2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 by the authors. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-5b1a3c671811af9f61ef2b0b7a2f5ba08f0ace2425f96ed614bfaad6648278e33</citedby><cites>FETCH-LOGICAL-c421t-5b1a3c671811af9f61ef2b0b7a2f5ba08f0ace2425f96ed614bfaad6648278e33</cites><orcidid>0000-0002-6167-5832 ; 0000-0003-4903-0908</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750536/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750536/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35008336$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Classe, Jean-Marc</creatorcontrib><creatorcontrib>Asselain, Bernard</creatorcontrib><creatorcontrib>Campion, Loic</creatorcontrib><creatorcontrib>Berton, Dominique</creatorcontrib><creatorcontrib>Frenel, Jean-Sébastien</creatorcontrib><creatorcontrib>Lécuru, Fabrice</creatorcontrib><creatorcontrib>Ferron, Gwenael</creatorcontrib><creatorcontrib>Gladieff, Laurence</creatorcontrib><creatorcontrib>Bourgin, Charlotte</creatorcontrib><creatorcontrib>Loaec, Cecile</creatorcontrib><title>Survival Outcomes after Hyperthermic Intraperitoneal Chemotherapy for a First Ovarian Cancer Relapse: A Systematic Evidence-Based Review</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>Hyperthermic intraperitoneal chemotherapy (HIPEC) is routinely used in the treatment of a first ovarian cancer relapse.
This systematic review, in accordance with Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, aimed to assess the quality of scientific proof of the survival benefits of HIPEC, using Medline and Google Scholar. Qualitative analysis using the Oxford CEBM Levels of Evidence 2011 grading is reported.
Of 469 articles identified, 23 were included; 15 based on series of patients treated with HIPEC without a control group, and 8 case control series of patients treated with or without HIPEC. The series without a control group showed median overall survival (OS) ranged from 23.5 to 63 months, highlighting a broad standard deviation. Considering the case control series, OS was significantly better in the HIPEC group in 5 studies, and similar in 1. The current review showed considerable heterogeneity and biases, with an Oxford Level of Evidence grading of 4 for 22 selected series and 2 for one.
There is no strong evidence to suggest efficacy of HIPEC in improving survival of patients treated for a first relapse of ovarian cancer due to the low quality of the data.</description><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Morbidity</subject><subject>Ovarian cancer</subject><subject>Patients</subject><subject>Surgery</subject><subject>Survival</subject><subject>Systematic Review</subject><subject>Tumors</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkUtr3DAUhUVpaUKadXdF0E03TvSwZbuLQjrkBYGBJF2ba_mqo2BbriS7zD_Iz44mSUMabaTL-XS4h0PIZ86OpKzZsYZRow88Z5zxUrwj-4KVIlOqzt-_eu-RwxDuWDpS8lKVH8meLBirpFT75P5m9otdoKfrOWo3YKBgInp6sZ3Qxw36wWp6OUYPabbRjZjY1QYHtxNh2lLjPAV6Zn2IdL2AtzDS1eNq9Bp7mAJ-pyf0ZhsiDhCT2-liO0x69hMCdglaLP79RD4Y6AMePt8H5NfZ6e3qIrtan1-uTq4ynQses6LlILUqecU5mNoojka0rC1BmKIFVhkGGkUuClMr7BTPWwPQKZVXoqxQygPy48l3mtsBO427aH0zeTuA3zYObPO_MtpN89stTVUWrJAqGXx7NvDuz4whNoMNGvseRnRzaITiVc2qutqhX9-gd272Y4r3SAlWs6JM1PETpb0LwaN5WYazZld086bo9OPL6wwv_L9a5QOrS6hD</recordid><startdate>20211230</startdate><enddate>20211230</enddate><creator>Classe, Jean-Marc</creator><creator>Asselain, Bernard</creator><creator>Campion, Loic</creator><creator>Berton, Dominique</creator><creator>Frenel, Jean-Sébastien</creator><creator>Lécuru, Fabrice</creator><creator>Ferron, Gwenael</creator><creator>Gladieff, Laurence</creator><creator>Bourgin, Charlotte</creator><creator>Loaec, Cecile</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6167-5832</orcidid><orcidid>https://orcid.org/0000-0003-4903-0908</orcidid></search><sort><creationdate>20211230</creationdate><title>Survival Outcomes after Hyperthermic Intraperitoneal Chemotherapy for a First Ovarian Cancer Relapse: A Systematic Evidence-Based Review</title><author>Classe, Jean-Marc ; Asselain, Bernard ; Campion, Loic ; Berton, Dominique ; Frenel, Jean-Sébastien ; Lécuru, Fabrice ; Ferron, Gwenael ; Gladieff, Laurence ; Bourgin, Charlotte ; Loaec, Cecile</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-5b1a3c671811af9f61ef2b0b7a2f5ba08f0ace2425f96ed614bfaad6648278e33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Morbidity</topic><topic>Ovarian cancer</topic><topic>Patients</topic><topic>Surgery</topic><topic>Survival</topic><topic>Systematic Review</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Classe, Jean-Marc</creatorcontrib><creatorcontrib>Asselain, Bernard</creatorcontrib><creatorcontrib>Campion, Loic</creatorcontrib><creatorcontrib>Berton, Dominique</creatorcontrib><creatorcontrib>Frenel, Jean-Sébastien</creatorcontrib><creatorcontrib>Lécuru, Fabrice</creatorcontrib><creatorcontrib>Ferron, Gwenael</creatorcontrib><creatorcontrib>Gladieff, Laurence</creatorcontrib><creatorcontrib>Bourgin, Charlotte</creatorcontrib><creatorcontrib>Loaec, Cecile</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Classe, Jean-Marc</au><au>Asselain, Bernard</au><au>Campion, Loic</au><au>Berton, Dominique</au><au>Frenel, Jean-Sébastien</au><au>Lécuru, Fabrice</au><au>Ferron, Gwenael</au><au>Gladieff, Laurence</au><au>Bourgin, Charlotte</au><au>Loaec, Cecile</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Survival Outcomes after Hyperthermic Intraperitoneal Chemotherapy for a First Ovarian Cancer Relapse: A Systematic Evidence-Based Review</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2021-12-30</date><risdate>2021</risdate><volume>14</volume><issue>1</issue><spage>172</spage><pages>172-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Hyperthermic intraperitoneal chemotherapy (HIPEC) is routinely used in the treatment of a first ovarian cancer relapse.
This systematic review, in accordance with Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, aimed to assess the quality of scientific proof of the survival benefits of HIPEC, using Medline and Google Scholar. Qualitative analysis using the Oxford CEBM Levels of Evidence 2011 grading is reported.
Of 469 articles identified, 23 were included; 15 based on series of patients treated with HIPEC without a control group, and 8 case control series of patients treated with or without HIPEC. The series without a control group showed median overall survival (OS) ranged from 23.5 to 63 months, highlighting a broad standard deviation. Considering the case control series, OS was significantly better in the HIPEC group in 5 studies, and similar in 1. The current review showed considerable heterogeneity and biases, with an Oxford Level of Evidence grading of 4 for 22 selected series and 2 for one.
There is no strong evidence to suggest efficacy of HIPEC in improving survival of patients treated for a first relapse of ovarian cancer due to the low quality of the data.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>35008336</pmid><doi>10.3390/cancers14010172</doi><orcidid>https://orcid.org/0000-0002-6167-5832</orcidid><orcidid>https://orcid.org/0000-0003-4903-0908</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2021-12, Vol.14 (1), p.172 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8750536 |
| source | PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Cancer therapies Chemotherapy Clinical trials Morbidity Ovarian cancer Patients Surgery Survival Systematic Review Tumors |
| title | Survival Outcomes after Hyperthermic Intraperitoneal Chemotherapy for a First Ovarian Cancer Relapse: A Systematic Evidence-Based Review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T13%3A33%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Survival%20Outcomes%20after%20Hyperthermic%20Intraperitoneal%20Chemotherapy%20for%20a%20First%20Ovarian%20Cancer%20Relapse:%20A%20Systematic%20Evidence-Based%20Review&rft.jtitle=Cancers&rft.au=Classe,%20Jean-Marc&rft.date=2021-12-30&rft.volume=14&rft.issue=1&rft.spage=172&rft.pages=172-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers14010172&rft_dat=%3Cproquest_pubme%3E2618209057%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2618209057&rft_id=info:pmid/35008336&rfr_iscdi=true |